These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 30549256

  • 1. Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.
    Liew DFL, Leung JLY, Liu B, Cebon J, Frauman AG, Buchanan RRC.
    Int J Rheum Dis; 2019 Feb; 22(2):297-302. PubMed ID: 30549256
    [Abstract] [Full Text] [Related]

  • 2. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
    Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, Rischin A, Frauman AG, Kee D, Smith K, Brady B, Rischin D, Gibson A, Mileshkin L, Klein O, Weickhardt A, Arulananda S, Shackleton M, McArthur G, Östör A, Cebon J, Solomon B, Buchanan RR, Wicks IP, Lo S, Hicks RJ, Sandhu S.
    Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628
    [Abstract] [Full Text] [Related]

  • 3. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J, Sánchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Leví A, Arranz R, Lorenzo A, Gullón P, Donnay O, Adrados M, Costas P, Aspa J, Alfranca A, Mondéjar R, Colomer R.
    Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
    [Abstract] [Full Text] [Related]

  • 4. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.
    Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot JM, Lambotte O, Le Pavec J, De Martin E, Balleyguier C, Champiat S, Ammari S.
    Eur J Cancer; 2018 Jun; 96():91-104. PubMed ID: 29698933
    [Abstract] [Full Text] [Related]

  • 5. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y.
    JAMA Oncol; 2019 Mar 01; 5(3):376-383. PubMed ID: 30589930
    [Abstract] [Full Text] [Related]

  • 6. Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series.
    Shazib MA, Woo SB, Sroussi H, Carvo I, Treister N, Farag A, Schoenfeld J, Haddad R, LeBoeuf N, Villa A.
    Oral Dis; 2020 Mar 01; 26(2):325-333. PubMed ID: 31642136
    [Abstract] [Full Text] [Related]

  • 7. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.
    Narváez J, Juarez-López P, LLuch J, Narváez JA, Palmero R, García Del Muro X, Nolla JM, Domingo-Domenech E.
    Autoimmun Rev; 2018 Oct 01; 17(10):1040-1045. PubMed ID: 30103042
    [Abstract] [Full Text] [Related]

  • 8. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N.
    BMC Cancer; 2019 Oct 21; 19(1):974. PubMed ID: 31638948
    [Abstract] [Full Text] [Related]

  • 9. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
    Hall KH, Liu Y, Jiang C, Harvey RD.
    Pharmacotherapy; 2020 Feb 21; 40(2):133-141. PubMed ID: 31863604
    [Abstract] [Full Text] [Related]

  • 10. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, Bracarda S, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierto PA.
    Eur J Cancer; 2020 Mar 21; 128():17-26. PubMed ID: 32109847
    [Abstract] [Full Text] [Related]

  • 11. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L.
    Oncologist; 2019 Aug 21; 24(8):1128-1136. PubMed ID: 31015312
    [Abstract] [Full Text] [Related]

  • 12. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
    Ghosh N, Tirpack A, Chan KK, Bass AR.
    J Immunother Cancer; 2020 Oct 21; 8(2):. PubMed ID: 33067320
    [Abstract] [Full Text] [Related]

  • 13. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O.
    Lancet Haematol; 2019 Jan 21; 6(1):e48-e57. PubMed ID: 30528137
    [Abstract] [Full Text] [Related]

  • 14. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL, Patel G, Chiesa-Fuxench ZC, McGettigan S, Schuchter L, Mitchell TC, Ming ME, Chu EY.
    JAMA Dermatol; 2018 Sep 01; 154(9):1057-1061. PubMed ID: 30027278
    [Abstract] [Full Text] [Related]

  • 15. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
    Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Sabbatini R, Bracarda S, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, Iacono D, Migliorino MR, Rossi A, Porzio G, Cannita K, Ciciarelli V, Fargnoli MC, Ascierto PA, Ficorella C.
    Oncologist; 2019 Jun 01; 24(6):e327-e337. PubMed ID: 30796151
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.
    Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.
    Eur J Cancer; 2018 Mar 01; 91():21-29. PubMed ID: 29331748
    [Abstract] [Full Text] [Related]

  • 17. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM.
    Curr Oncol; 2018 Oct 01; 25(5):e403-e410. PubMed ID: 30464691
    [Abstract] [Full Text] [Related]

  • 18. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
    Matsuoka H, Hayashi T, Takigami K, Imaizumi K, Shiroki R, Ohmiya N, Sugiura K, Kawada K, Sawaki A, Maeda K, Ando Y, Uyama I.
    BMC Cancer; 2020 Jul 14; 20(1):656. PubMed ID: 32664888
    [Abstract] [Full Text] [Related]

  • 19. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
    Zhao JJ, Wen XZ, Ding Y, Li DD, Zhu BY, Li JJ, Weng DS, Zhang X, Zhang XS.
    Aging (Albany NY); 2020 Jun 08; 12(11):10663-10675. PubMed ID: 32516130
    [Abstract] [Full Text] [Related]

  • 20. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
    Min Lee CK, Li S, Tran DC, Zhu GA, Kim J, Kwong BY, Chang ALS.
    J Am Acad Dermatol; 2018 Dec 08; 79(6):1047-1052. PubMed ID: 29857011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.